Aptus Pharma to host virtual investor meet on Sep 25

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Aptus Pharma to host virtual investor meet on Sep 25
  • Session part of Arihant Capital Bharat Connect conference
  • Management interaction scheduled from 3:00 pm to 4:00 pm
  • Intimation filed under Regulation 30 of Listing Regulations
powered bylight_fuzz_icon
51182101

*this image is generated using AI for illustrative purposes only.

Aptus Pharma Limited will host a virtual investor interaction on September 25, 2026, as part of the Arihant Capital Bharat Connect conference.

The management team is scheduled to participate in the "Rising Stars" session from 3:00 pm to 4:00 pm. The company issued this intimation pursuant to Regulation 30 of the SEBI Listing Regulations.

Event Details

Detail Information
Date September 25, 2026
Time 3:00 pm – 4:00 pm
Platform Arihant Capital: Bharat Connect
Format Virtual Group Meeting

Discussions during the session will be based on publicly available information. The company noted that changes to the schedule may occur due to exigencies on the part of participants or the company.

The intimation was signed by Managing Director Tejash Hathi and filed with the BSE Ltd on September 17, 2026.

Historical Stock Returns for Aptus Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
-1.99%+1.91%+31.57%+149.86%+920.92%+920.92%

What specific growth metrics or strategic initiatives is Aptus Pharma likely to highlight to justify its inclusion in the 'Rising Stars' session?

How might the management's commentary on the pharmaceutical sector's outlook influence investor sentiment and stock valuation in the short term?

Are there any pending regulatory approvals or clinical trial results that Aptus Pharma may address during this virtual interaction?

Aptus Pharma shareholders unanimously approve preferential allotment at 16th AGM

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Shareholders unanimously approved all three resolutions at the 16th AGM with 100% assent
  • Special resolution for preferential allotment of equity shares passed without dissent
  • Promoter group voted in favour with 1,25,00,000 shares; public non-institutions with 14,38,000 shares
  • Total of 130 members participated via remote e-voting, representing 1,39,38,000 votes
  • Statutory and secretarial audit reports contained no qualifications or adverse remarks
powered bylight_fuzz_icon
50941221

*this image is generated using AI for illustrative purposes only.

Aptus Pharma shareholders unanimously approved all three resolutions at its 16th Annual General Meeting held on September 14, 2026. The special resolution for the preferential allotment of equity shares passed with 100% assent, alongside the adoption of financial statements and director re-appointment.

The meeting was conducted via video conferencing and other audio-visual means in compliance with SEBI Listing Regulations and the Companies Act, 2013. A live webcast was facilitated for stakeholders unable to attend virtually.

Voting Results

The scrutinizer’s report, submitted by Company Secretary Nalin Ganatra, confirmed that all votes were cast via remote e-voting, with no dissent recorded across any shareholder category. A total of 130 members voted, representing 1,39,38,000 shares out of the total eligible shares on the record date of September 7, 2026.

Resolution-wise Breakdown

Resolution Type Votes In Favour Votes Against Result
Adoption of Audited Financials (FY26) Ordinary 1,39,38,000 0 Passed
Re-appointment of Chetan Shantilal Lalseta Ordinary 1,39,38,000 0 Passed
Preferential Allotment of Equity Shares Special 1,39,38,000 0 Passed

Promoter and promoter group shareholders held 1,25,00,000 shares and voted entirely in favour. Public non-institutional shareholders held 14,38,000 shares and also voted unanimously in favour. No institutional public shareholders participated in the voting process.

Attendance and Governance

Mr. Chetan Shantilal Lalseta, Chairman, presided over the meeting. The requisite quorum under Section 103 of the Act was present throughout. A total of 28 members attended the meeting via video conferencing: four from the promoter group and 24 from the public category.

Directors Present

Name Designation Location
Chetan Shantilal Lalseta Director & Chairman Rajkot
Tejash Maheshchandra Hathil Managing Director Rajkot
Riddhish Natwarlal Tanna Director & SROC Chairman Rajkot
Sejal Harit Palan Independent Director & Audit Committee Chairperson Rajkot
Vikas Rambhai Jobanputra Independent Director & NRC Chairman Anand
Jyotiben Hasmukhbhai Chandarana Director Rajkot

Key managerial personnel in attendance included Ghanshyam Vinubhai Pansuriya (CEO), Kapilbhai Hasmukhbhai Chandarana (CFO), and Mohini Hardikbhai Gandhi (Company Secretary).

Audit Reports

The statutory auditors’ report on the financial statements for the year ended March 31, 2026, and the secretarial audit report contained no qualifications, reservations, adverse remarks, or disclaimers. Consequently, these reports were not read out during the meeting as per regulatory guidelines.

Remote e-voting was open from September 11, 2026, to September 13, 2026. Voting facilities remained available during the meeting and for 15 minutes after its conclusion.

Historical Stock Returns for Aptus Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
-1.99%+1.91%+31.57%+149.86%+920.92%+920.92%

What is the specific strategic purpose and timeline for the capital raised through the approved preferential allotment of equity shares?

How might the absence of institutional public shareholder participation in the AGM impact future investor confidence or liquidity for Aptus Pharma?

Will the new equity issuance lead to significant dilution for existing public shareholders, and how does the company plan to mitigate this concern?

More News on Aptus Pharma

1 Year Returns:+920.92%